Immutep
Open
$0.36
Prev. Close
$0.36
High
$0.36
Low
$0.36
Market Snapshot
$52.02M
-6.5
-1.02
$19.26M
31
Immutep Ltd. is a clinical stage biotechnology company, which engages in the development of LAG-3 related immunotherapeutic products for cancer and autoimmune diseases. The company is headquartered in Sydney, New South Wales. The firm is focused on developing novel immunotherapies for cancer and autoimmune disease. The company is focused on advancement of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), and its diversified product portfolio harnesses LAG-3’s ability to stimulate or suppress the immune response. Its lead clinical candidate is eftilagimod alfa (efti or IMP321) for the treatment of different types of cancers. Efti is the Company’s first-in-class novel immunotherapy that directly activates the immune system to fight cancer, which is under evaluation in TACTI-004 (KEYNOTE-F91), a registrational Phase III trial for the first-line therapy of advanced or metastatic non-small cell lung cancer. Its second in-house product candidate (IMP761) which is in clinical development for the treatment of autoimmune disease, a third product candidate, IMP731, a depleting antibody that could remove T cells involved in autoimmunity.
Immutep Ltd. is a clinical stage biotechnology company, which engages in the development of LAG-3 related immunotherapeutic products for cancer and autoimmune diseases. The company is headquartered in Sydney, New South Wales. The firm is focused on developing novel immunotherapies for cancer and autoimmune disease. The company is focused on advancement of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), and its diversified product portfolio harnesses LAG-3’s ability to stimulate or suppress the immune response. Its lead clinical candidate is eftilagimod alfa (efti or IMP321) for the treatment of different types of cancers. Efti is the Company’s first-in-class novel immunotherapy that directly activates the immune system to fight cancer, which is under evaluation in TACTI-004 (KEYNOTE-F91), a registrational Phase III trial for the first-line therapy of advanced or metastatic non-small cell lung cancer. Its second in-house product candidate (IMP761) which is in clinical development for the treatment of autoimmune disease, a third product candidate, IMP731, a depleting antibody that could remove T cells involved in autoimmunity.
Recently from Cashu
Immutep Under Legal Investigation After TACTI-004 Phase III Study Halted
Immutep Faces Legal Scrutiny After Phase III Study Termination Immutep Ltd. is currently under investigation by the Rosen Law Firm, a leading global entity specializing in investor rights, over allega…
Immutep's TACTI-004 Trial Marks Crucial Turning Point for Future Development and Market Viability
Immutep Faces Critical Juncture in TACTI-004 Phase 3 Trial Immutep Limited, a biopharmaceutical company focusing on immunotherapy for cancer treatment, currently stands at a pivotal point as it naviga…
Immutep's TACTI-004 Trial Update Sparks Investor Concerns Over Future Growth Prospects
Immutep's TACTI-004 Trial Update Raises Concerns Immutep Limited's recent update regarding its TACTI-004 Phase 3 trial brings significant attention to the challenges that biotech companies face during…
Immutep Advances Autoimmune Therapy with IMP761 Trial Update on LAG-3 Agonist
Immutep Advances in Autoimmune Disease Treatment with IMP761 Trial Update Immutep Limited (NASDAQ: IMMP) announces a significant update on its Phase I clinical trial for IMP761, a groundbreaking LAG-3…